AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.62 |
Market Cap | 63.33M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.36 |
PE Ratio (ttm) | -1.83 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.68 |
Volume | 49,686 |
Avg. Volume (20D) | 275,521 |
Open | 0.60 |
Previous Close | 0.62 |
Day's Range | 0.60 - 0.66 |
52-Week Range | 0.43 - 1.23 |
Beta | undefined |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company ope...
Analyst Forecast
According to 4 analyst ratings, the average rating for VNRX stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 657.69% from the latest price.